только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 7 / 8
Страница 3 / 4

Литература / References

Внимание! Часть функций, например, копирование текста к себе в конспект, озвучивание и т.д. могут быть доступны только в режиме постраничного просмотра.Режим постраничного просмотра
 

21. Федеральный закон «О качестве и безопасности пищевых продуктов» от 02.01.2000 г. № 29-ФЗ [Federal Law «On Quality and Safety of Foodstuffs» of 02.01.2000, No. 29-FZ(In Russ.)] URL: https://rg.ru/2000/01/02/ produkty-dok.html.

22. Федеральный закон от 01.03.2020 г. № 47-ФЗ «О внесении изменений в Федеральный закон «О качестве и безопасности пищевых продуктов» и статью 37 Федерального закона «Об образовании в Российской Федерации» [Federal Law No. 47-FZ of 01.03.2020 “On Amendments to the Federal Law ‘On Quality and Safety of Foodstuffs’ and Article 37 of the Federal Law ‘On Education in the Russian Federation’” (In Russ.)] URL: https:// rg.ru/2020/03/03/pitanie-dok.html.

23. ГОСТ Р 55577-2013. Национальный стандарт Российской Федерации. Продукты пищевые специализированные и функциональные. Информация об отличительных признаках и эффективности. [GOST P 55577-2013. National Standard of the Russian Federation. Specialised and functional food products. Information on distinguishing characters and efficacy (In Russ.)] URL: https:// internet-law.ru/gosts/gost/55874/

24. ГОСТ Р 54059-2010. Национальный стандарт Российской Федерации. Продукты пищевые функциональные. Ингредиенты пищевые функциональные. Классификация и общие требования. [GOST R 54059-2010. National Standard of the Russian Federation. Functional food products. Functional food ingredients. Classification and general requirements (In Russ.)] URL: https://internet-law. ru/gosts/gost/50895/

25. Shi L.H., Balakrishnan K., Thiagarajah K., Mohd Ismail N.I., Yin O.S. Beneficial Properties of Probiotics. Trop Life Sci Res. 2016;27(2):73–90. DOI: 10.21315/ tlsr2016.27.2.6

26. Ishibashi N., Yamazaki S. Probiotics and safety. Am J Clin Nutr. 2001;73(2 Suppl):465S–470. DOI: 10.1093/ ajcn/73.2.465s

27. de Vos P., Faas M.M., Spasojevic M.M., Sikkema J. Encapsulation for preservation of functionality and targeted delivery of bioactive food components. Int Dairy J. 2010;20:292–302. DOI: 10.1016/j.idairyj.2009.11.008

28. Burgain J., Gaiani C., Linder M., Scher J. Encapsulation of probiotic living cells: from laboratory scale to industrial applications. J Food Eng. 2011;104:467–83. DOI: 10.1016/j.jfoodeng.2010.12.031

29. Salas-Jara M., Ilabaca A., Vega M., García A. Biofilm forming Lactobacillus: new challenges for the development of probiotics. Microorganisms. 2016;4(3):35. DOI: 10.3390/microorganisms4030035

30. Tsai Y.L., Lin T.L., Chang C.J., Wu T.R., Lai W.F., Lu C.C., Lai H.C. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci. 2019;26(1):3. DOI: 10.1186/ s12929-018-0493-6

31. Howick J., Chalmers I., Glasziou P., Greenhalgh T., Heneghan C., Liberati A., et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence (Background Document). Oxford Centre for Evidence-Based Medicine. https://www.cebm. net/index.aspx?o=5653

32. Allen S.J., Martinez E.G., Gregorio G.V., Dans L.F. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;(11):CD003048. DOI: 10.1002/14651858.CD003048.pub3

33. Höchter W., Hagenhoff G. Saccharomyces boulardii in acute adult diarrhea: efficacy and tolerability of treatment. Munch Med Wochenschr. 1990;(132):188–92.

34. Grossi E., Buresta R., Abbiati R., Cerutti R., Pro-DIA study group. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with acute diarrhea: a multicenter, randomized study in primary care. J Clin Gastroenterol. 2010;44 Suppl 1:S35–41. DOI: 10.1097/ MCG.0b013e3181e103f4

35. Hempel S., Newberry S.J., Maher A.R., Wang Z., Miles J.N.V., Shanman R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959–69. DOI: 10.1001/jama.2012.3507

36. Ouwehand A.C., Dong-Lian C., Weijian X., Ste wart M., Ni J., Stewart T., et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32(4):458–63

37. Chatterjee S., Kar P., Das T., Ray S., Gangulyt S., Rajendiran C., et al. Randomised placebocontrolled double blind multicenteric trial on efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium BB-12 for prevention of antibiotic-associated diarrhoea. J Assoc Physicians India. 2013;61(10):708–12.

38. Hickson M., D’Souza A.L., Muthu N., Rogers T.R., Want S., Rajkumar C., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007;335(7610):80. DOI: 10.1136/bmj.39231.599815.55

39. Cimperman L., Bayless G., Best K., Diligente A., Mordarski B., Oster M., et al. A randomized, double-blind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol. 2011;45(9):785– 9. DOI: 10.1097/MCG.0b013e3182166a42

40. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5:CD006095. DOI: 10.1002/14651858.CD006095.pub4

41. Lewis S., Burmeister S., Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol. 2005;3(5):442–8. DOI: 10.1016/s1542- 3565(04)00677-9

42. Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori. A network meta-analysisMedicine (Baltimore). 2019;98(15):e15180. DOI: 10.1097/ MD.0000000000015180

43. Dang Y., Reinhardt J.D., Zhou X., Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PloS One. 2014;9(11):e111030. DOI: 10.1371/journal.pone.0111030

44. Ojetti V., Bruno G., Ainora M.E., Gigante G., Rizzo G., Roccarina D., et al. Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy. Gastroenterol Res Pract. 2012;2012:740381. DOI: 10.1155/2012/740381

45. Ли И.А., Сильвестрова С.Ю., Дроздов В.Н. Пробиотик Риофлора Баланс Нео и антихеликобактерная терапия — повышение эффективности лечения за счет снижения нежелательных явлений. Медицинский Совет. 2013;10:100–3. [ Li I.A., Silvestrova S.Yu., Drozdov V.N. “Rioflora Balans Neo” probiotic and anti-Helicobacter therapy: increased efficacy at reduced adverse events. Medical Council. 2013;(10):100–3 (In Russ.)]. DOI: 10.21518/2079-701X-2013-10-100-103

46. Ducrotté P., Sawant P., Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012–8. DOI: 10.3748/wjg.v18.i30.4012

47. Ford A.C., Quigley E.M., Lacy B.E., Lembo A.J., Saito Y.A., Schiller L.R., et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547–61; quiz 1546, 1562. DOI: 10.1038/ajg.2014.202

48. Choi C.H., Jo S.Y., Park H.J., Chang S.K., Byeon J.S., Myung S.J. A randomized, double-blind, placebocontrolled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol. 2011;45(8):679–83. DOI: 10.1097/ MCG.0b013e318204593e

49. Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D., O’Mahony L., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006;101(7):1581–90. DOI: 10.1111/j.1572- 0241.2006.00734.x

50. Moayyedi P., Ford A.C., Talley N.J., Cremonini F., Foxx-Orenstein A.E., Brandt L.J., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325–32. DOI: 10.1136/gut.2008.167270

51. Lorenzo-Zúñiga V., Llop E., Suárez C., Álvarez B., Abreu L., Espadaler J., et al. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20(26):8709– 16. DOI: 10.3748/wjg.v20.i26.8709

52. Ivashkin V., Drapkina O., Poluektova Ye., Kuchumova S., Sheptulin A., Shifrin O. The Effect of a Multistrain Probiotic on the Symptoms and Small Intestinal Bacterial Overgrowth in Constipation-predominant Irritable Bowel Syndrome: A Randomized, Simple-blind, Placebo-controlled Trial. American Journal of Clinical Medicine Research. 2015;3(2):18–23. DOI: 10.12691/ajcmr-3-2-1

53. Guyonnet D., Schlumberger A., Mhamdi L., Jakob S., Chassany O. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomized, double-blind, parallel, controlled study. British Journal of Nutrition, 2009;102(11):1654– 62. DOI: 10.1111/j.1365-2036.2007.03362.x

54. Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch Iran Med. 2014;17(7):466–70. DOI: 0141707/AIM.003

55. Yang Y.X., He M., Hu G., Wei J., Pages P., Yang X.H., et al. Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J Gastroenterol. 2008;14(40):6237–43. DOI: 10.3748/wjg.14.6237

56. Ojetti V., Ianiro G., Tortora A., D’Angelo G., Di Rienzo T.A., Bibbò S., et al. The effect of Lactobacillus reuteri supplementation in adults with chronic functional constipation: a randomized, double-blind, placebo-controlled trial. J Gastrointest Liver Dis JGLD. 2014;23(4):387–91. DOI: 10.15403/jgld.2014.1121.234.elr

57. Schumann C. Medical, nutritional and technological properties of lactulose. An update. Eur J Nutr. 2002;41 Suppl 1:I17–25. DOI: 10.1007/s00394-002-1103-6

58. Nyman M. Fermentation and bulking capacity of indigestible carbohydrates: the case of inulin and oligofructose.

Br J Nutr. 2002;87 Suppl 2:S163–8. DOI: 10.1079/BJNBJN/2002533

59. Eales J., Gibson P.R., Whorwell P.J., Kellow J., Yellowlees A., Perry R., et al. Systematic review and metaanalysis: the effects of fermented milk with Bifidobacterium lactis CNCM I-2494 and lactic acid bacteria on gastrointestinal discomfort in the general adult population. Therap Adv Gastroenterol. 2017;10(1):74–88. DOI: 10.1177/1756283X16670075

60. Gluud L.L., Vilstrup H., Morgan M.Y. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016;4:CD003044. DOI: 10.1002/14651858. CD003044.pub3

61. Szajewska H., Guarino A., Hojsak I., Indrio F., Kolacek S., Shamir R., et al.; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr.

2014;58(4):531–9. DOI: 10.1097/MPG.0000000000000320

62. Szajewska H., Skórka A., Ruszczyński M., GieruszczakBiałek D. Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children--updated analysis of randomised controlled trials. Aliment Pharmacol Ther. 2013;38(5):467–76. DOI: 10.1111/apt.12403

63. Szajewska H., Skórka A. Saccharomyces boulardii for treating acute gastroenteritis in children: updated metaanalysis of randomized controlled trials. Aliment Pharmacol Ther. 2009;30(9):960–1. DOI: 10.1111/j.13652036.2009.04113.x

64. Szajewska H., Kołodziej M. Systematic review with metaanalysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42(10):1149–57. DOI: 10.1111/apt.13404